Unsupported Browser
The American College of Surgeons website is not compatible with Internet Explorer 11, IE 11. For the best experience please update your browser.
Menu
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
Become a member and receive career-enhancing benefits

Our top priority is providing value to members. Your Member Services team is here to ensure you maximize your ACS member benefits, participate in College activities, and engage with your ACS colleagues. It's all here.

Become a Member
ACS
ACS Health Policy Alert

A Proposed Medicare Payment Cut You Should Know About - Modifier 25 & Overlapping Services, Part 1

August 2026

A Proposed Medicare Payment Cut You Should Know About - Modifier 25 & Overlapping Services, Part 1
The Issue

The Centers for Medicare & Medicaid Services (CMS) has proposed reducing Medicare payment when certain procedures are performed during the same visit as a significant, separately identifiable evaluation and management (E/M) service. Under the proposal, payment for the lower-valued service would be reduced by 50%.

Why It Matters

Surgeons may provide two distinct, medically necessary services during a single patient visit. Automatically reducing payment when those services occur together could undervalue physician work and create unintended consequences for patients, including additional appointments, travel, time away from work or family, and potential delays in care.

What the ACS Found

ACS researchers analyzed Medicare claims and found that 1,458 procedures would be affected based on current use patterns, spanning a broad range of surgical specialties.

In one example, a patient who receives both an evaluation and an anoscopy during the same visit would see the total valuation of those services fall from 3.14 to 2.87 relative value units (wRVUs)—an 8.6% reduction for the same encounter.

The findings illustrate how the proposed policy could affect the valuation of distinct services provided during the same patient visit.

Read A Proposed Medicare Payment Cut You Should Know About - Modifier 25 & Overlapping Services, Part 2.

Meet the Authors

Christopher P. Childers, MD, PhD
Department of Surgery, University of Washington, Seattle, WA; Fred Hutch Cancer Center, Seattle, WA

Don J. Selzer, MD, MS, FACS
Department of Surgery, Indiana University, Indianapolis, IN

Thomas C. Tsai, MD, MPH, FACS
American College of Surgeons, Washington, DC; Department of Surgery, Brigham and Women’s Hospital, Boston, MA; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health

Want to access a print-friendly version?

Hot Topics in the 2027 Physician Fee Schedule – Modifier 25 & Overlapping Services, Part 1

On July 14, CMS released its proposed rule for the 2027 Medicare physician fee schedule (PFS). Among the more debated proposals is a policy to reduce payment when procedures are performed on the same day as an outpatient evaluation and management (E/M) service. This article introduces the proposal, presents data on the services and specialties most affected, and describes the central areas of controversy.

It has long been Medicare policy that when multiple procedures are performed on the same day, the additional procedures may be subject to a payment reduction. Based in part on data and analysis performing during the creation of the relative value unit (RVU) system, this reduction is generally accepted to be 50% of the value of the additional service. This concept is perhaps easiest to understand in the context of the operating room. If a surgeon removes a large abdominal tumor but must also perform a right colectomy because the tumor has invaded the colon, the surgeon receives credit for both the mass excision and the colectomy. However, the colectomy is not valued at its full rate because some preoperative and postoperative work overlaps, and there may be modest time savings associated with performing the procedures during the same operative session.

When a procedure is performed on the same day as a clinic visit, however, Medicare has historically paid the full value of both services as long as the clinician attests that the work associated with the E/M service is significant and separately identifiable from the procedure. The physician does this by appending modifier 25 to the E/M code.

For example (Table 1), if a patient presents to a colorectal surgeon’s office for evaluation of bright red blood per rectum, the surgeon will perform a comprehensive history and physical examination and supplement the evaluation with an anoscopy—a small scope inserted through the anus to allow more detailed visual inspection. Under the current CMS proposal, the wRVUs associated with the lesser-valued service—in this case, the anoscopy—would be reduced by half, decreasing the total valuation of the encounter from 3.14 to 2.87 wRVUs (8.6% total reduction).

 
Current wRVUs
Adjustment Under CMS Proposal
Proposed wRVUs

New Patient Office Visit (99204)

2.60

None

2.60

Anoscopy

0.54

50% reduction

0.27

Total Encounter

3.14

 

2.87

Table 1: Example of the Proposed Policy on an Office Visit with a Colorectal Surgeon
 
Current wRVUs
Adjustment Under CMS Proposal
Proposed wRVUs

New Patient Office Visit (99204)

2.60

None

2.60

Anoscopy

0.54

50% reduction

0.27

Total Encounter

3.14

 

2.87

Using the 2024 Medicare 5% Carrier File, we found that nearly 4,400 procedures in the Medicare PFS would be eligible for this policy, although only 1,458 would be affected based on some proportion of their utilization occurring on the same day as an office-based E/M service. While many of these services are uncommon, several procedures and specialties would be substantially affected. Table 2 presents the 20 procedures most affected by the policy based on the volume of services impacted. Table 3 presents the 25 physician specialties most affected based on overall volume, along with the three most common impacted procedures within each specialty. Dermatology would experience a disproportionate impact from the proposed change, although effects would extend broadly across many office-based specialties.

The comment period for this proposal, as well as the broader PFS rule, remains open through mid-September. Our thoughts and the common themes shared by physician and specialty organizations center around the following issues:

First, the policy could incentivize providers to separate office visits and procedures onto separate days in order to capture the full value of each service. This would be inconvenient for patients and providers alike and worse, could delay care and paradoxically increase cost to patients through the extra transportation, parking, child care, time off of work etc.

Second, the actual mechanism for implementing this policy is not clear. Currently, modifier 25 is appended to the E/M service. But CMS proposal is more complicated—to pay 50% of the lower valued service on the same day as a modifier 25. Billers/coders will have to be specifically trained on this new policy creating additional administrative burden for an already taxed workforce. There is also no discussion of how to deal with nuanced situations—for example, if multiple procedures are performed or if add-on (ZZZ) codes are also billed the same day.

Third, the issue of overlapping work is already incorporated into procedural RVU valuations. When the AMA’s Relative Value Scale Update Committee (RUC) generates recommendations for office-based procedures they use intentionally thin pre- and post-service packages to account for this issue. CMS is fully aware of this, suggesting this policy is not trying to account for redundant work, but is instead trying to devalue the procedure itself. 

Fourth, is the concept itself. The hallmark of high-quality procedural care is not only the technical procedural elements, but in the comprehensive evaluation and counseling of the patient to make sure the procedure being recommended is the right procedure, for the right patient, for the right indication, and at the right time. This policy represents a de-valuation of either that shared decision making framework or the technical skill required to perform the procedure safely.

Finally, and perhaps most importantly, this policy addresses only one category of overlapping work within the PFS—overlap between procedures and E/M services. Current policies already account for overlapping work among procedures, and the proposed policy would extend this concept to procedures performed alongside E/M services. But there is a much larger area of the PFS that this new policy ignores—how should Medicare address overlapping work among multiple E/M service themselves?  This issue will be the focus of the second portion of this series.

CPT
Description
Work RVU
Global Period
Approximate 2024 Utilization
Proportion Billed with E&M Visit

17000

Destruction premalignant lesion

0.61

10

6,299,780

87.4%

11102

Tangential biopsy of skin

0.66

0

3,497,580

83.9%

20610

Arthrocentesis, major joint

0.79

0

4,806,620

56.2%

17110

Destruction benign lesions, up to 14 lesions

0.7

10

3,200,900

83.8%

11721

Debride nails, 6 or more

0.54

0

5,344,160

21.9%

69210

Remove impacted ear wax

0.61

0

1,502,280

67.7%

17004

Destruction benign lesions, 15 or more

1.37

10

858,720

87.8%

67028

Injection eye drug

1.44

0

3,582,260

18.8%

31231

Diagnostic nasal endoscopy

1.1

0

746,240

83.3%

20550

Injection into a single tendon/sheath

0.75

0

770,780

77.3%

20611

Arthrocentesis, major joint, with ultrasound

1.1

0

1,059,420

51.9%

11042

Debridement, subcutaneous tissue, <=20 square cm

1.01

0

2,011,240

24.6%

31575

Diagnostic laryngoscopy

0.94

0

546,140

88.9%

11056

Paring/cutting hyperkeratotic lesion, 2-4 lesions

0.5

0

1,832,440

20.9%

52000

Cystoscopy

1.53

0

830,140

37.6%

20600

Arthrocentesis, small joint

0.66

0

422,860

70.1%

11720

Debride nails, 1-5

0.32

0

1,844,580

13.5%

20605

Arthrocentesis, intermediate joint

0.68

0

347,120

71.1%

97597

Debridement, open wound, <=20 square cm

0.77

0

673,440

31.1%

11104

Punch biopsy, single lesion

0.83

0

285,460

67.3%

Data derived from the 2024 5% Medicare Carrier File and Addendum B of the Final Rule. Analysis was limited to claims with 000, 010, and 090 global period procedures. Assistant at surgery (e.g., modifier 80, AS) lines were excluded. The proportion of claims with an associated office evaluation & management code were identified (99202-5, 99211-5). Volume estimates were multiplied by 20 to generate approximate national volumes.

Table 2: Top 20 Procedures by Volume with Concurrent Office Visits
CPT
Description
Work RVU
Global Period
Approximate 2024 Utilization
Proportion Billed with E&M Visit

17000

Destruction premalignant lesion

0.61

10

6,299,780

87.4%

11102

Tangential biopsy of skin

0.66

0

3,497,580

83.9%

20610

Arthrocentesis, major joint

0.79

0

4,806,620

56.2%

17110

Destruction benign lesions, up to 14 lesions

0.7

10

3,200,900

83.8%

11721

Debride nails, 6 or more

0.54

0

5,344,160

21.9%

69210

Remove impacted ear wax

0.61

0

1,502,280

67.7%

17004

Destruction benign lesions, 15 or more

1.37

10

858,720

87.8%

67028

Injection eye drug

1.44

0

3,582,260

18.8%

31231

Diagnostic nasal endoscopy

1.1

0

746,240

83.3%

20550

Injection into a single tendon/sheath

0.75

0

770,780

77.3%

20611

Arthrocentesis, major joint, with ultrasound

1.1

0

1,059,420

51.9%

11042

Debridement, subcutaneous tissue, <=20 square cm

1.01

0

2,011,240

24.6%

31575

Diagnostic laryngoscopy

0.94

0

546,140

88.9%

11056

Paring/cutting hyperkeratotic lesion, 2-4 lesions

0.5

0

1,832,440

20.9%

52000

Cystoscopy

1.53

0

830,140

37.6%

20600

Arthrocentesis, small joint

0.66

0

422,860

70.1%

11720

Debride nails, 1-5

0.32

0

1,844,580

13.5%

20605

Arthrocentesis, intermediate joint

0.68

0

347,120

71.1%

97597

Debridement, open wound, <=20 square cm

0.77

0

673,440

31.1%

11104

Punch biopsy, single lesion

0.83

0

285,460

67.3%

Data derived from the 2024 5% Medicare Carrier File and Addendum B of the Final Rule. Analysis was limited to claims with 000, 010, and 090 global period procedures. Assistant at surgery (e.g., modifier 80, AS) lines were excluded. The proportion of claims with an associated office evaluation & management code were identified (99202-5, 99211-5). Volume estimates were multiplied by 20 to generate approximate national volumes.

The AWV was introduced by CMS as 2 G-codes (G0438 and G0439) in 2011 to implement preventive care provisions of the Affordable Care Act. These services describe initial and subsequent AWVs that include a personalized prevention plan. Although the codes have never been formally surveyed by the AMA Relative Value Scale Update Committee (RUC), their work RVUs were updated in 2021 to maintain parity with comparable office visit valuations.

AWVs are performed almost exclusively by family physicians, internists, and advanced practice providers. In a follow-up analysis, we used the same data source and identified all claims containing an AWV code. There were just under 11 million such claims in 2024. We then examined the frequency and types of additional services billed on the same claim.

Annual wellness visits were billed alone only 37 percent of the time (Table 3). In the remaining 63 percent of claims, at least one additional service was reported, and multiple additional services were common. The most common additional services were a level 3 or 4 office visit, advanced care planning, and screening for alcohol misuse and depression.

Specialty

Procedures without E&M

Procedures with E&M

Proportion of Procedures with E&M

Top 3 Codes Billed with E&M

Dermatology

4,355,740

9,004,940

67%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17110 (Destruction benign lesions, up to 14 lesions)

Physician Assistant

2,446,000

4,308,380

64%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17110 (Destruction benign lesions, up to 14 lesions)

Podiatry

11,276,720

3,617,580

24%

11721 (Debride nails, 6 or more)
11056 (Paring/cutting hyperkeratotic lesion, 2-4 lesions)
11720 (Debride nails, 1-5)

Orthopedic Surgery

2,938,200

2,183,420

43%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20550 (Injection into a single tendon/sheath)

Nurse Practitioner

2,400,560

2,117,160

47%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17110 (Destruction benign lesions, up to 14 lesions)

Otolaryngology

1,021,420

2,056,680

67%

69210 (Remove impacted ear wax)
31231 (Diagnostic nasal endoscopy)
31575 (Diagnostic laryngoscopy)

Ophthalmology

6,314,320

1,007,960

14%

67028 (Injection eye drug)
68761 (Close tear duct opening)
66821 (Discission of secondary membranous cataract)

Family Practice

919,900

796,920

46%

20610 (Arthrocentesis, major joint)
17000 (Destruction premalignant lesion)
69210 (Remove impacted ear wax)

Urology

2,093,620

596,720

22%

52000 (Cystoscopy)
51702 (Insert temp bladder cath)
51700 (Irrigation of bladder)

Internal Medicine

810,540

358,180

31%

20610 (Arthrocentesis, major joint)
69210 (Remove impacted ear wax uni)
17000 (Destruction premalignant lesion)

Hand Surgery

338,660

322,440

49%

20550 (Injection into a single tendon/sheath)
20600 (Arthrocentesis, major joint)
20605 (Arthrocentesis, major joint)

Physical Medicine and Rehabilitation

974,960

287,960

23%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20553 (Inject trigger points, 3 or more)

Sports Medicine

226,260

257,980

53%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20550 (Injection into a single tendon/sheath)

Rheumatology

71,280

221,280

76%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20600 (Arthrocentesis, major joint)

Micrographic Dermatologic Surgery (MDS)

392,420

186,380

32%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17311 (Mohs, first stage, up to 5 blocks)

Obstetrics/Gynecology

403,040

180,420

31%

51701 (Insert bladder catheter)
57160 (Insert pessary/other device)
58100 (Biopsy of uterus lining)

General Surgery

1,895,620

165,340

8%

11042 (Debridement, subcutaneous tissue, <=20 square cm)
46600 (Diagnostic anoscopy)
97597 (Debridement, open wound, <=20 square cm)

Pain Management

927,420

132,960

13%

20610 (Arthrocentesis, major joint)
20553 (Inject trigger points, 3 or more)
20552 (Inject trigger points, 1-2)

Neurology

326,860

118,040

27%

64615 (Chemodenervation of muscles; for migraine)
64405 (Injection, occipital nerve
64616 (Chemodeneveration; neck)

Plastic and Reconstructive Surgery

461,680

109,380

19%

20550 (Injection into a single tendon/sheath)
11042 (Debridement, subcutaneous tissue, <=20 square cm
17000 (Destruction premalignant lesion)

Optometry

538,980

105,520

16%

68761 (Close tear duct opening)
67820 (Revise eyelashes)
65778 (Cover eye w/membrane)

Osteopathic Manipulative Therapy

36,700

105,240

74%

98929 (Osteopath manj 9-10 regions)
98928 (Osteopath manj 7-8 regions)
98927 (Osteopath manj 5-6 regions)

Anesthesiology

1,906,280

104,560

5%

62323 (Injection, lumbar/sacral)
20610 (Arthrocentesis, major joint)
20553 (Inject trigger points, 3 or more)

Colorectal Surgery

208,520

89,700

30%

46600 (diagnostic anoscopy)
46221 (ligation of hemorrhoids)
45300 (proctosigmoidoscopy)

Emergency Medicine

825,940

84,580

9%

11042 (Debridement, subcutaneous tissue, <=20 square cm
20610 (Arthrocentesis, major joint)
97597 (Debridement, open wound, <=20 square cm)

Data derived from the 2024 5% Medicare Carrier File and Addendum B of the Final Rule. Analysis was limited to claims with 000, 010, and 090 global period procedures. Assistant at surgery (e.g., modifier 80, AS) lines were excluded. The proportion of claims with a concomitant office evaluation & management code were identified (99202-5, 99211-5). Volume estimates were multiplied by 20 to generate approximate national volumes. The top 25 specialties were identified based on volume of procedures with an E&M code.

Table 3: Top 25 Impacted Specialties by Volume of Procedures with Concurrent Office Visits

Specialty

Procedures without E&M

Procedures with E&M

Proportion of Procedures with E&M

Top 3 Codes Billed with E&M

Dermatology

4,355,740

9,004,940

67%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17110 (Destruction benign lesions, up to 14 lesions)

Physician Assistant

2,446,000

4,308,380

64%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17110 (Destruction benign lesions, up to 14 lesions)

Podiatry

11,276,720

3,617,580

24%

11721 (Debride nails, 6 or more)
11056 (Paring/cutting hyperkeratotic lesion, 2-4 lesions)
11720 (Debride nails, 1-5)

Orthopedic Surgery

2,938,200

2,183,420

43%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20550 (Injection into a single tendon/sheath)

Nurse Practitioner

2,400,560

2,117,160

47%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17110 (Destruction benign lesions, up to 14 lesions)

Otolaryngology

1,021,420

2,056,680

67%

69210 (Remove impacted ear wax)
31231 (Diagnostic nasal endoscopy)
31575 (Diagnostic laryngoscopy)

Ophthalmology

6,314,320

1,007,960

14%

67028 (Injection eye drug)
68761 (Close tear duct opening)
66821 (Discission of secondary membranous cataract)

Family Practice

919,900

796,920

46%

20610 (Arthrocentesis, major joint)
17000 (Destruction premalignant lesion)
69210 (Remove impacted ear wax)

Urology

2,093,620

596,720

22%

52000 (Cystoscopy)
51702 (Insert temp bladder cath)
51700 (Irrigation of bladder)

Internal Medicine

810,540

358,180

31%

20610 (Arthrocentesis, major joint)
69210 (Remove impacted ear wax uni)
17000 (Destruction premalignant lesion)

Hand Surgery

338,660

322,440

49%

20550 (Injection into a single tendon/sheath)
20600 (Arthrocentesis, major joint)
20605 (Arthrocentesis, major joint)

Physical Medicine and Rehabilitation

974,960

287,960

23%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20553 (Inject trigger points, 3 or more)

Sports Medicine

226,260

257,980

53%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20550 (Injection into a single tendon/sheath)

Rheumatology

71,280

221,280

76%

20610 (Arthrocentesis, major joint)
20611 (Arthrocentesis, major joint, with ultrasound)
20600 (Arthrocentesis, major joint)

Micrographic Dermatologic Surgery (MDS)

392,420

186,380

32%

17000 (Destruction premalignant lesion)
11102 (Tangential biopsy of skin)
17311 (Mohs, first stage, up to 5 blocks)

Obstetrics/Gynecology

403,040

180,420

31%

51701 (Insert bladder catheter)
57160 (Insert pessary/other device)
58100 (Biopsy of uterus lining)

General Surgery

1,895,620

165,340

8%

11042 (Debridement, subcutaneous tissue, <=20 square cm)
46600 (Diagnostic anoscopy)
97597 (Debridement, open wound, <=20 square cm)

Pain Management

927,420

132,960

13%

20610 (Arthrocentesis, major joint)
20553 (Inject trigger points, 3 or more)
20552 (Inject trigger points, 1-2)

Neurology

326,860

118,040

27%

64615 (Chemodenervation of muscles; for migraine)
64405 (Injection, occipital nerve
64616 (Chemodeneveration; neck)

Plastic and Reconstructive Surgery

461,680

109,380

19%

20550 (Injection into a single tendon/sheath)
11042 (Debridement, subcutaneous tissue, <=20 square cm
17000 (Destruction premalignant lesion)

Optometry

538,980

105,520

16%

68761 (Close tear duct opening)
67820 (Revise eyelashes)
65778 (Cover eye w/membrane)

Osteopathic Manipulative Therapy

36,700

105,240

74%

98929 (Osteopath manj 9-10 regions)
98928 (Osteopath manj 7-8 regions)
98927 (Osteopath manj 5-6 regions)

Anesthesiology

1,906,280

104,560

5%

62323 (Injection, lumbar/sacral)
20610 (Arthrocentesis, major joint)
20553 (Inject trigger points, 3 or more)

Colorectal Surgery

208,520

89,700

30%

46600 (diagnostic anoscopy)
46221 (ligation of hemorrhoids)
45300 (proctosigmoidoscopy)

Emergency Medicine

825,940

84,580

9%

11042 (Debridement, subcutaneous tissue, <=20 square cm
20610 (Arthrocentesis, major joint)
97597 (Debridement, open wound, <=20 square cm)

Data derived from the 2024 5% Medicare Carrier File and Addendum B of the Final Rule. Analysis was limited to claims with 000, 010, and 090 global period procedures. Assistant at surgery (e.g., modifier 80, AS) lines were excluded. The proportion of claims with a concomitant office evaluation & management code were identified (99202-5, 99211-5). Volume estimates were multiplied by 20 to generate approximate national volumes. The top 25 specialties were identified based on volume of procedures with an E&M code.